Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Intravesical EOquin After TUR in Superficial Bladder Cancer
2006-002372-18Phase 2Active
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jun 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apaziquone in bladder cancer, sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoints: Safety of single immediate post-TUR intravesical EOquin and Pharmacokinetics of EOquin after intravesical instillation. Started Jun 2006; status: active.
02
Drugs
apaziquone
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2006-002372-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002372-18.